MK-677 (Ibutamoren): Oral GH Secretagogue Studies Guide

MK-677, also known as Ibutamoren, is the only orally bioavailable growth hormone secretagogue in widespread laboratory use. Unlike peptide-based GHRPs that require subcutaneous injection, MK-677 is a non-peptide small molecule that mimics ghrelin at the GH secretagogue receptor (GHSR-1a), stimulating growth hormone and IGF-1 elevation through once-daily oral administration.

This combination — meaningful GH/IGF-1 elevation without injections — makes MK-677 one of the most studied compounds for GH-axis modulation, sleep quality, body composition, and bone metabolism.

What Is MK-677?

MK-677 is a non-peptide ghrelin receptor agonist (GHSR-1a agonist) developed by Merck in the 1990s as part of a program to find orally active growth hormone secretagogues. Its chemical name is Ibutamoren mesylate, and its molecular structure is a spiroindoline derivative — fundamentally different from the peptide GHRPs (Ipamorelin, GHRP-2, GHRP-6) despite sharing the same receptor target.

| Property | Value | |----------|-------| | Classification | Non-peptide GHSR-1a agonist | | Molecular weight | ~624 Da (mesylate salt) | | Bioavailability | Oral — approximately 60–70% | | Half-life | ~24 hours | | GH pattern | Sustained elevation (24-hour) | | Dosing frequency | Once daily | | Primary study outcomes | IGF-1 elevation, body composition, sleep, bone density |

Why Oral Bioavailability Matters

Peptide GH secretagogues (Ipamorelin, GHRP-2, CJC-1295) are destroyed by digestive enzymes when taken orally and require subcutaneous injection. MK-677's small molecule, non-peptide structure resists this enzymatic degradation, allowing it to be absorbed intact from the GI tract and reach systemic circulation in biologically active form.

This fundamentally changes the practical study profile: once-daily oral dosing rather than multiple daily injections.

Mechanism of Action

MK-677 acts as a ghrelin mimetic — it binds and activates the GHSR-1a receptor with similar affinity to endogenous ghrelin, but with a much longer half-life (~24 hours vs. ghrelin's ~30 minutes).

Receptor Signaling

GHSR-1a activation by MK-677:

1. Activates Gαq/11 G-protein
2. Stimulates phospholipase C (PLC)
3. Generates IP3 → triggers calcium release from endoplasmic reticulum
4. Calcium-dependent exocytosis of GH secretory granules from pituitary somatotrophs

The same mechanism as injectable GHRPs like Ipamorelin — but sustained over 24 hours rather than 2–3 hours.

IGF-1 Mediation

The majority of MK-677's anabolic and body composition effects are mediated through IGF-1 (Insulin-like Growth Factor 1), produced by the liver in response to elevated GH. IGF-1 elevation:

• Stimulates skeletal muscle protein synthesis
• Promotes bone matrix formation and mineralization
• Supports connective tissue remodeling
• Has anti-catabolic effects on lean mass

Key Studies Findings

IGF-1 Elevation

Multiple published studies have documented MK-677's robust IGF-1 elevating effects:

• Nass et al. (2008) — 25 mg MK-677 daily in healthy older adults produced mean IGF-1 increases of 60–80% from baseline over 12 months
• Murphy et al. (1998) — Dose-dependent IGF-1 elevation with MK-677 at 10, 25, and 50 mg daily in healthy young and elderly subjects
• Chapman et al. (1996) — Landmark study in 32 obese men showing dose-dependent GH and IGF-1 elevation with sustained effects over 2-week treatment periods

The IGF-1 elevation with MK-677 is consistent, sustained, and dose-dependent — making it one of the most reliable IGF-1 elevating interventions documented in the scientific literature.

Sleep Quality: Deep Sleep Enhancement

One of MK-677's most replicated and clinically significant study findings is its improvement of slow-wave sleep (SWS) — the deepest, most restorative phase of the sleep cycle.

A landmark study by Copinschi et al. (1997) demonstrated in healthy young men that MK-677 administration significantly increased Stage 4 (deep sleep) duration and REM sleep, without disrupting overall sleep architecture. Key findings:

• Stage 3/4 (slow-wave sleep) increased significantly
• REM sleep duration increased
• No disruption of sleep onset or overall sleep efficiency
• GH secretion during sleep was substantially amplified

This finding is mechanistically coherent: GH naturally peaks during slow-wave sleep, and MK-677's sustained GHSR activation amplifies this nocturnal GH surge. The improvement in sleep quality appears to be independent of (and additive to) the GH/IGF-1 effects.

Bone Mineral Density

Multiple studies have documented MK-677's effects on bone:

• Snyder et al. demonstrated significant increases in bone mineral density (BMD) and bone turnover markers in elderly subjects after 12–18 months of MK-677 administration
• Effects were consistent with GH/IGF-1 stimulation of osteoblast activity and bone remodeling
• Both cortical and trabecular bone density improvements were documented

Lean Mass Preservation

Studies in catabolic states (caloric restriction, older adults with muscle loss) have shown MK-677 can:

• Attenuate muscle loss during caloric deficit
• Increase lean body mass in older adults with GH deficiency
• Preserve muscle cross-sectional area during periods of reduced activity

Dosing Protocols

| Dose | Typical Studies Context | Duration | |------|-------------------------|---------| | 10 mg/day | Low-dose protocol; elderly populations | 12–24 weeks | | 25 mg/day | Standard dose in most published studies | 12–24 weeks | | 50 mg/day | Exploratory dose (higher IGF-1, more side effects) | Limited |

Timing: The nighttime dosing approach is most commonly described for MK-677. Taking it 1–2 hours before sleep aligns with natural GH secretion patterns and maximizes the sleep quality effects.

Cortisol note: Some studies have shown a modest increase in morning cortisol with MK-677 (particularly at higher doses). For this reason, some scientists prefer nighttime dosing to minimize the cortisol exposure window during waking hours.

| Parameter | Recommendation in Studies | |-----------|--------------------------| | Dose | 10–25 mg once daily | | Timing | Evening (1–2 hours before sleep) | | Fasting requirement | Not required (unlike injectable GHRPs) | | Cycle duration | 12–24 weeks | | Off-period | 4–8 weeks between cycles |

Side Effects Documented in Studies

Unlike peptide GHRPs, MK-677's 24-hour sustained GHSR activation produces a different side effect profile that scientists should be aware of:

| Side Effect | Frequency | Mechanism | Notes | |------------|----------|-----------|-------| | Water retention | Common | GH-mediated sodium/water retention | Usually transient; resolves with dose reduction | | Increased appetite | Very common | Ghrelin mimicry (ghrelin is the "hunger hormone") | Expected with GHSR agonism | | Transient insulin resistance | Possible at higher doses | Sustained GH elevation can antagonize insulin | Monitor at doses ≥25 mg | | Morning lethargy/drowsiness | Occasional | Deep sleep augmentation; GH-related sedation | Usually resolves after 1–2 weeks | | Mild cortisol elevation | Possible | Indirect HPA axis modulation | Lower with evening dosing | | Joint pain/stiffness | Occasional | Fluid retention around joints | Dose-dependent; resolves with reduction |

Important: In Nass et al. (2008), 25 mg MK-677 daily over 12 months was generally well-tolerated in older adults, with water retention and increased appetite being the most common observations. Fasting insulin and insulin resistance markers increased modestly — a finding consistent with GH's known insulin-antagonizing effects.

MK-677 vs. Injectable GHRPs: Comparison

| Property | MK-677 | Ipamorelin | GHRP-2 | |----------|--------|------------|--------| | Route | Oral | SC injection | SC injection | | Half-life | ~24 hours | ~2 hours | ~1 hour | | GH pattern | Sustained elevation | Pulsatile (2–3 hr) | Pulsatile (1–2 hr) | | IGF-1 elevation | 60–80% documented | Moderate | Moderate-high | | Cortisol elevation | Minimal | Minimal | Moderate | | Prolactin elevation | Slight | Minimal | Significant | | Appetite stimulation | Significant | Minimal | Significant | | Water retention | More common | Less common | Moderate | | Sleep improvement | Documented | Not specifically studied | Not specifically studied | | Convenience | Very high (oral) | Moderate (injection) | Moderate (injection) |

Which is better? For scientists prioritizing physiological GH pulsatility and hormonal selectivity, injectable Ipamorelin is superior. For oral-only study contexts or sleep quality endpoints, MK-677 provides unique advantages that injectable GHRPs cannot match.

View MK-677 | View Ipamorelin | View CJC-1295

Storage and Handling

MK-677 is typically available as an oral capsule or liquid solution in study settings:

| Form | Storage | Duration | |------|---------|---------| | Capsule/powder | Room temperature, away from light | 12–24 months | | Liquid solution | Refrigerator (2–8°C) | 6–12 months | | Liquid solution | Room temperature | Shorter; check product specs |

Unlike peptide-based study compounds, MK-677 does not require lyophilization and is more stable at ambient temperatures. However, all formulations should be stored away from heat, moisture, and direct light.

Studies Disclaimer

Important: All information in this guide is provided for educational and educational purposes only. MK-677 (Ibutamoren) is not approved by the FDA or any regulatory body for human therapeutic use. It is sold as a study chemical for laboratory use only. This guide does not constitute medical advice. Always consult a licensed healthcare provider before considering any GH secretagogue protocol.